Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Buprenorphine"" wg kryterium: Temat


Tytuł:
Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial.
Autorzy:
McPherson SM; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States. Electronic address: .
Smith CL; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.
Hall L; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.
Miguel AQ; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.
Bowden T; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States; College of Nursing, Washington State University, Spokane, WA, United States.
Keever A; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.
Schmidt A; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.
Olson K; Ideal Option, Kennewick, WA, United States.
Rodin N; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, United States.
McDonell MG; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.
Roll JM; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States.
LeBrun J; Optimize Health,  5601 22nd Ave NW #200, Seattle, WA, United States.
Pokaż więcej
Źródło:
Drug and alcohol dependence [Drug Alcohol Depend] 2024 Mar 01; Vol. 256, pp. 111099. Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Humans ; Feasibility Studies ; Pilot Projects ; Buprenorphine, Naloxone Drug Combination ; Medication Adherence
Czasopismo naukowe
Tytuł:
There goes the neighborhood? The public safety enhancing effects of a mobile harm reduction intervention.
Autorzy:
Fixler AL; School of Social Work, University of Pittsburgh. 2117 Cathedral of Learning, 4200 Fifth Avenue, Pittsburgh, PA 15260, United States. Electronic address: .
Jacobs LA; School of Social Work, University of Pittsburgh. 2117 Cathedral of Learning, 4200 Fifth Avenue, Pittsburgh, PA 15260, United States.
Jones DB; Graduate School of Public and International Affairs, University of Pittsburgh, 3424 Wesley W. Posvar Hall, 230 South Bouquet Street, Pittsburgh, PA 15260, United States.
Arnold A; Prevention Point Pittsburgh, 5913 Penn Avenue, Pittsburgh, PA 15206, United States.
Underwood EE; School of Social Work, University of Pittsburgh. 2117 Cathedral of Learning, 4200 Fifth Avenue, Pittsburgh, PA 15260, United States.
Pokaż więcej
Źródło:
The International journal on drug policy [Int J Drug Policy] 2024 Feb; Vol. 124, pp. 104329. Date of Electronic Publication: 2024 Jan 16.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Humans ; Harm Reduction ; Health Promotion ; Buprenorphine, Naloxone Drug Combination/therapeutic use
Czasopismo naukowe
Tytuł:
Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada.
Autorzy:
Iacono A; Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
Wang T; ICES, V1 06, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
Tadrous M; University of Toronto Leslie Dan Faculty of Pharmacy, 144 College StToronto, Ontario M5S 3M2, Canada; ICES, V1 06, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada; Women's College Hospital, 76 Grenville St Toronto, Ontario M5S 1B2, Canada.
Campbell T; Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
Kolla G; Canadian Institute for Substance Use Research, 2300 McKenzie Ave, Victoria, British Columbia V8N 5M8, Canada.
Leece P; Women's College Hospital, 76 Grenville St Toronto, Ontario M5S 1B2, Canada; University of Toronto Department of Family and Community Medicine, 500 University Ave, Toronto, Ontario M5G 1V7, Canada; Public Health Ontario, 480 University Ave #300, Toronto, Ontario M5G 1V2, Canada; University of Toronto Dalla Lana School of Public Health, 155 College St Room 500, Toronto, Ontario M5T 3M7, Canada.
Sproule B; University of Toronto Leslie Dan Faculty of Pharmacy, 144 College StToronto, Ontario M5S 3M2, Canada; Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada; University of Toronto Department of Psychiatry, 250 College Street 8th floor, Toronto Ontario M5T 1R8, Canada.
Kleinman RA; Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada; University of Toronto Department of Psychiatry, 250 College Street 8th floor, Toronto Ontario M5T 1R8, Canada.
Besharah J; Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada; University of Toronto Leslie Dan Faculty of Pharmacy, 144 College StToronto, Ontario M5S 3M2, Canada; ICES, V1 06, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada; University of Toronto Institute for Health Policy, Management and Evaluation, 155 College St 4th Floor, Toronto Ontario M5T 3M6, Canada; Women's College Hospital, 76 Grenville St Toronto, Ontario M5S 1B2, Canada; Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada; University of Toronto Department of Psychiatry, 250 College Street 8th floor, Toronto Ontario M5T 1R8, Canada; Canadian Institute for Substance Use Research, 2300 McKenzie Ave, Victoria, British Columbia V8N 5M8, Canada; University of Toronto Department of Family and Community Medicine, 500 University Ave, Toronto, Ontario M5G 1V7, Canada; Public Health Ontario, 480 University Ave #300, Toronto, Ontario M5G 1V2, Canada; University of Toronto Dalla Lana School of Public Health, 155 College St Room 500, Toronto, Ontario M5T 3M7, Canada; Ontario Drug Policy Research Network Lived Experience Advisory Group, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
Munro C; Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada; University of Toronto Leslie Dan Faculty of Pharmacy, 144 College StToronto, Ontario M5S 3M2, Canada; ICES, V1 06, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada; University of Toronto Institute for Health Policy, Management and Evaluation, 155 College St 4th Floor, Toronto Ontario M5T 3M6, Canada; Women's College Hospital, 76 Grenville St Toronto, Ontario M5S 1B2, Canada; Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada; University of Toronto Department of Psychiatry, 250 College Street 8th floor, Toronto Ontario M5T 1R8, Canada; Canadian Institute for Substance Use Research, 2300 McKenzie Ave, Victoria, British Columbia V8N 5M8, Canada; University of Toronto Department of Family and Community Medicine, 500 University Ave, Toronto, Ontario M5G 1V7, Canada; Public Health Ontario, 480 University Ave #300, Toronto, Ontario M5G 1V2, Canada; University of Toronto Dalla Lana School of Public Health, 155 College St Room 500, Toronto, Ontario M5T 3M7, Canada; Ontario Drug Policy Research Network Lived Experience Advisory Group, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
Doolittle M; Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada; University of Toronto Leslie Dan Faculty of Pharmacy, 144 College StToronto, Ontario M5S 3M2, Canada; ICES, V1 06, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada; University of Toronto Institute for Health Policy, Management and Evaluation, 155 College St 4th Floor, Toronto Ontario M5T 3M6, Canada; Women's College Hospital, 76 Grenville St Toronto, Ontario M5S 1B2, Canada; Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada; University of Toronto Department of Psychiatry, 250 College Street 8th floor, Toronto Ontario M5T 1R8, Canada; Canadian Institute for Substance Use Research, 2300 McKenzie Ave, Victoria, British Columbia V8N 5M8, Canada; University of Toronto Department of Family and Community Medicine, 500 University Ave, Toronto, Ontario M5G 1V7, Canada; Public Health Ontario, 480 University Ave #300, Toronto, Ontario M5G 1V2, Canada; University of Toronto Dalla Lana School of Public Health, 155 College St Room 500, Toronto, Ontario M5T 3M7, Canada; Ontario Drug Policy Research Network Lived Experience Advisory Group, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
Gomes T; Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada; University of Toronto Leslie Dan Faculty of Pharmacy, 144 College StToronto, Ontario M5S 3M2, Canada; ICES, V1 06, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada; University of Toronto Institute for Health Policy, Management and Evaluation, 155 College St 4th Floor, Toronto Ontario M5T 3M6, Canada. Electronic address: .
Pokaż więcej
Źródło:
Drug and alcohol dependence [Drug Alcohol Depend] 2024 Jan 01; Vol. 254, pp. 111032. Date of Electronic Publication: 2023 Nov 19.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Adult ; Humans ; Narcotic Antagonists/therapeutic use ; Ontario ; Cohort Studies ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Analgesics, Opioid/therapeutic use
Czasopismo naukowe
Tytuł:
Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians.
Autorzy:
MacKinnon N; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Emergency Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Lane D; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.
Scheuermeyer F; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Emergency Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.; Center for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.
Kaczorowski J; Université de Montréal, Montreal, Quebec, Canada.
Dong K; Department of Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada.
Orkin AM; Department of Family & Community Medicine, University of Toronto, Toronto, Ontario, Canada.
Daoust R; Université de Montréal, Montreal, Quebec, Canada.; Centre de Recherche de l'Hôpital Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
Moe J; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
Andolfatto G; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.
Klaiman M; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Yan J; Division of Emergency Medicine, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Koh JJ; Department of Emergency Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Crowder K; Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada.
Atkinson P; Department of Emergency Medicine, Dalhousie University, St. John, New Brunswick, Canada.
Savage D; Division of Clinical Sciences, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada.
Stempien J; Department of Emergency Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Besserer F; Department of Emergency Medicine, University of British Columbia, Prince George, British Columbia, Canada.
Wale J; Department of Emergency Medicine, University of British Columbia, Victoria, British Columbia, Canada.
Kestler A; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Emergency Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.; Center for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.; British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 05; Vol. 19 (2), pp. e0297084. Date of Electronic Publication: 2024 Feb 05 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/epidemiology
Opioid-Related Disorders*/complications
Humans ; Narcotic Antagonists/therapeutic use ; Canada/epidemiology ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Emergency Service, Hospital ; Cognition ; Naloxone/therapeutic use
Czasopismo naukowe
Tytuł:
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Autorzy:
Opheim A; Department of Addiction Medicine, Haukeland University Hospital, Norway; Institute of Global Public Health and Primary Care, University of Bergen, Norway. Electronic address: .
Benth JŠ; Institute of Clinical Medicine, Campus Ahus, University of Oslo, P.O.Box 1171, 0318 Blindern, Norway; Health Services Research Unit, Akershus University Hospital, P.O. Box 1000, 1478 Lorenskog, Norway.
Solli KK; Norwegian Centre for Addiction Research, University of Oslo, 0315 Oslo, Norway,; Department of Research and Development in Mental Health Services, Akershus University Hospital, 1478 Lorenskog, Norway; Vestfold Hospital Trust, 3116 Tonsberg, Norway.
Kloster PS; Department of Addiction Medicine, Haukeland University Hospital, Norway.
Fadnes LT; Department of Addiction Medicine, Haukeland University Hospital, Norway; Institute of Global Public Health and Primary Care, University of Bergen, Norway.
Kunøe N; Lovisenberg Diaconal Hospital, P.O. Box 4970, 0440 Oslo, Norway.
Gaulen Z; Department of Addiction Medicine, Haukeland University Hospital, Norway; Department of Clinical Dentistry, University of Bergen, Norway.
Tanum L; Department of Research and Development in Mental Health Services, Akershus University Hospital, 1478 Lorenskog, Norway; Faculty for Health Science, Oslo Metropolitan University, Pilestredet 32, 0167 Oslo, Norway.
Pokaż więcej
Źródło:
Contemporary clinical trials [Contemp Clin Trials] 2023 Dec; Vol. 135, pp. 107360. Date of Electronic Publication: 2023 Oct 19.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article
MeSH Terms:
Opioid-Related Disorders*/drug therapy
Buprenorphine*
Male ; Humans ; Female ; Narcotic Antagonists/therapeutic use ; Naltrexone/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Analgesics, Opioid/therapeutic use ; Chronic Disease ; Recurrence ; Delayed-Action Preparations/therapeutic use ; Injections, Intramuscular
Czasopismo naukowe
Tytuł:
Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Autorzy:
Eugenia Socias M; British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada; Department of Medicine, University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada. Electronic address: .
Choi JC; British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada.
Fairbairn N; British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada; Department of Medicine, University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada.
Johnson C; British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada; School of Nursing, University of British Columbia, T201-2211 Wesbrook Mall. Vancouver, BC V6T 2B, Canada.
Wilson D; British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada.
Debeck K; British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada; Simon Fraser University Faculty of Health Sciences, 8888 University Drive, Burnaby, BC V5A 1S6, Canada.
Brar R; Department of Family Practice, University of British Columbia, 5950 University Boulevard, Vancouver, BC V6T 1Z3, Canada; Regional Addiction Program, Vancouver Coastal Health, Vancouver, BC, Canada.
Hayashi K; British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada; Simon Fraser University Faculty of Health Sciences, 8888 University Drive, Burnaby, BC V5A 1S6, Canada.
Pokaż więcej
Źródło:
The International journal on drug policy [Int J Drug Policy] 2023 Aug; Vol. 118, pp. 104075. Date of Electronic Publication: 2023 May 22.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/epidemiology
Opioid-Related Disorders*/epidemiology
Buprenorphine*/therapeutic use
Humans ; Analgesics, Opioid/therapeutic use ; Interrupted Time Series Analysis ; Pandemics ; British Columbia/epidemiology ; Methadone/therapeutic use ; Buprenorphine, Naloxone Drug Combination ; Morphine Derivatives ; Opiate Substitution Treatment
Czasopismo naukowe
Tytuł:
Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments.
Autorzy:
Stone KD; Department of Psychiatry, University of Calgary, Calgary, AB, Canada.
Scott K; Emergency Strategic Clinical Network™, Alberta Health Services, Edmonton, AB, Canada.
Holroyd BR; Emergency Strategic Clinical Network™, Alberta Health Services, Edmonton, AB, Canada.; Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.
Lang E; Emergency Strategic Clinical Network™, Alberta Health Services, Edmonton, AB, Canada.; Department of Emergency Medicine, University of Calgary, Calgary, AB, Canada.
Yee K; Data and Analytics (DIMR), Alberta Health Services, Edmonton, AB, Canada.
Taghizadeh N; Emergency Strategic Clinical Network™, Alberta Health Services, Edmonton, AB, Canada.; Department of Emergency Medicine, University of Calgary, Calgary, AB, Canada.
Deol J; Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.
Dong K; Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.
Fanaeian J; Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.
Ghosh M; Department of Psychiatry, University of Calgary, Calgary, AB, Canada.; Department of Medicine, University of Calgary, Calgary, AB, Canada.; Department of General Internal Medicine, University of Alberta, Edmonton, AB, Canada.
Low K; Emergency Strategic Clinical Network™, Alberta Health Services, Edmonton, AB, Canada.
Ross M; Department of Emergency Medicine, University of Calgary, Calgary, AB, Canada.
Tanguay R; Department of Psychiatry, University of Calgary, Calgary, AB, Canada.; Department of Surgery, University of Calgary, Calgary, AB, Canada.
Faris P; Data and Analytics (DIMR), Alberta Health Services, Edmonton, AB, Canada.
Day N; Virtual Opioid Dependency Program, Alberta Health Services, Edmonton, AB, Canada.
McLane P; Emergency Strategic Clinical Network™, Alberta Health Services, Edmonton, AB, Canada. .; Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada. .
Pokaż więcej
Źródło:
CJEM [CJEM] 2023 Jul; Vol. 25 (7), pp. 598-607. Date of Electronic Publication: 2023 May 28.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/epidemiology
Humans ; Narcotic Antagonists/therapeutic use ; Alberta/epidemiology ; Quality Improvement ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Emergency Service, Hospital ; Referral and Consultation ; Analgesics, Opioid/therapeutic use
Czasopismo naukowe
Tytuł:
Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Autorzy:
Mocanu V; British Columbia Centre on Substance Use, Vancouver, BC, Canada.
Bozinoff N; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health (CAMH), Toronto, ON, Canada.
Wood E; British Columbia Centre on Substance Use, Vancouver, BC, Canada; Department of Medicine, Faculty of Medicine, University of British Columbia, University of British Columbia, Vancouver, BC, Canada.
Jutras-Aswad D; Research Centre, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
Le Foll B; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health (CAMH), Toronto, ON, Canada; Department of Pharmacology and Toxicology, Faculty of Medicine, Medical Sciences Building, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Acute Care Program, CAMH, Toronto, ON, Canada.
Lim R; Department of Family Medicine and Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Cheol Choi J; British Columbia Centre on Substance Use, Vancouver, BC, Canada.
Yin Mok W; British Columbia Centre on Substance Use, Vancouver, BC, Canada.
Eugenia Socias M; British Columbia Centre on Substance Use, Vancouver, BC, Canada; Department of Medicine, Faculty of Medicine, University of British Columbia, University of British Columbia, Vancouver, BC, Canada. Electronic address: .
Pokaż więcej
Corporate Authors:
OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse
Źródło:
Drug and alcohol dependence [Drug Alcohol Depend] 2023 Jul 01; Vol. 248, pp. 109932. Date of Electronic Publication: 2023 May 18.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article
MeSH Terms:
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/complications
Buprenorphine*/therapeutic use
Humans ; Analgesics, Opioid/therapeutic use ; Opiate Substitution Treatment/methods ; Canada ; Methadone/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Prescriptions
Czasopismo naukowe
Tytuł:
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Autorzy:
Bakouni H; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Quebec, Montréal, Canada.
McAnulty C; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Quebec, Montréal, Canada.; Department of Psychiatry and Addictology, Université de Montréal, Québec, Montréal, Canada.
Tatar O; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Quebec, Montréal, Canada.; Department of Psychiatry and Addictology, Université de Montréal, Québec, Montréal, Canada.
Socias ME; British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.; Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Foll BL; Department of Pharmacology and Toxicology, Faculty of Medicine, Medical Sciences Building, University of Toronto, Ontario, Toronto, Canada.; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Ontario, Toronto, Canada.; Department of Psychiatry, University of Toronto, Ontario, Toronto, Canada.; Dalla Lana School of Public Health, University of Toronto, Ontario, Toronto, Canada.; Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health (CAMH), Ontario, Toronto, Canada.; Waypoint Research Institute, Waypoint Centre for Mental Health Care, Ontario, Penetanguishene, Canada.
Lim R; Department of Family Medicine and Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Ahamad K; British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.; Department of Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Jutras-Aswad D; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Quebec, Montréal, Canada.; Department of Psychiatry and Addictology, Université de Montréal, Québec, Montréal, Canada.
Pokaż więcej
Corporate Authors:
OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse
Źródło:
The American journal on addictions [Am J Addict] 2023 Sep; Vol. 32 (5), pp. 469-478. Date of Electronic Publication: 2023 Jun 12.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Opioid-Related Disorders*/drug therapy
Buprenorphine*/adverse effects
Humans ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Methadone/adverse effects ; Analgesics, Opioid/adverse effects ; Heroin ; Opiate Substitution Treatment/adverse effects ; Opiate Substitution Treatment/methods ; Canada ; Prescriptions ; Narcotic Antagonists/adverse effects
Czasopismo naukowe
Tytuł:
A mobile addiction service for community-based overdose prevention.
Autorzy:
Pepin MD; UMass Memorial Health, Worcester, MA, United States.; Department of Emergency Medicine, UMass Chan Medical School, Worcester, MA, United States.
Joseph JK; UMass Memorial Health, Worcester, MA, United States.; Department of Family Medicine and Community Health, UMass Chan Medical School, Worcester, MA, United States.
Chapman BP; UMass Memorial Health, Worcester, MA, United States.; Department of Emergency Medicine, UMass Chan Medical School, Worcester, MA, United States.
McAuliffe C; UMass Memorial Health, Worcester, MA, United States.; Department of Emergency Medicine, UMass Chan Medical School, Worcester, MA, United States.
O'Donnell LK; UMass Memorial Health, Worcester, MA, United States.
Marano RL; UMass Memorial Health, Worcester, MA, United States.; Department of Emergency Medicine, UMass Chan Medical School, Worcester, MA, United States.
Carreiro SP; UMass Memorial Health, Worcester, MA, United States.; Department of Emergency Medicine, UMass Chan Medical School, Worcester, MA, United States.
Garcia EJ; UMass Memorial Health, Worcester, MA, United States.; Department of Family Medicine and Community Health, UMass Chan Medical School, Worcester, MA, United States.
Silk H; UMass Memorial Health, Worcester, MA, United States.; Department of Family Medicine and Community Health, UMass Chan Medical School, Worcester, MA, United States.
Babu KM; UMass Memorial Health, Worcester, MA, United States.; Department of Emergency Medicine, UMass Chan Medical School, Worcester, MA, United States.
Pokaż więcej
Źródło:
Frontiers in public health [Front Public Health] 2023 Jul 19; Vol. 11, pp. 1154813. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).
Typ publikacji:
Case Reports; Research Support, Non-U.S. Gov't
MeSH Terms:
Opioid-Related Disorders*/prevention & control
Opioid-Related Disorders*/drug therapy
Buprenorphine*/therapeutic use
Drug Overdose*/drug therapy
Drug Overdose*/prevention & control
Humans ; Community Health Services ; Naloxone/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use
Raport
Tytuł:
Patients' experiences with continuation or discontinuation of buprenorphine before painful procedures: A brief report.
Autorzy:
Hathaway DB; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Bhat JA; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Twark C; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Rodriguez C; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Suzuki J; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Pokaż więcej
Źródło:
The American journal on addictions [Am J Addict] 2023 Jul; Vol. 32 (4), pp. 410-414. Date of Electronic Publication: 2023 Feb 27.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Humans ; Analgesics, Opioid/therapeutic use ; Pain/drug therapy ; Buprenorphine, Naloxone Drug Combination/therapeutic use
Czasopismo naukowe
Tytuł:
Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.
Autorzy:
Murray JP; Department of Medicine, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA. .
Pucci G; Department of Pharmacology, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
Weyer G; Department of Medicine, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
Ari M; Department of Medicine, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
Dickson S; Department of Medicine, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
Kerins A; Department of Pharmacology, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
Pokaż więcej
Źródło:
Addiction science & clinical practice [Addict Sci Clin Pract] 2023 Jun 01; Vol. 18 (1), pp. 38. Date of Electronic Publication: 2023 Jun 01.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Humans ; Analgesics, Opioid/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Retrospective Studies ; Opiate Substitution Treatment/methods ; Pain/drug therapy ; Pain/chemically induced
Czasopismo naukowe
Tytuł:
Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Autorzy:
Enns B; Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.
Krebs E; Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Whitehurst DGT; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Jutras-Aswad D; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 Saint-Denis Street, Montréal, QuébecH2X 0A9, Canada; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, 2900 boul. Edouard-Montpetit, Montréal, QuébecH3T1J4, Canada.
Le Foll B; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, OntarioM5S 1A8, Canada; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, 250 College Street, 8th floor, Toronto, OntarioM5T 1R8, Canada; Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, OntarioM5T 3M7, Canada; Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health (CAMH), 33 Ursula Franklin Street, Toronto, OntarioM5S 2S1, Canada; Acute Care Program, CAMH, 33 Ursula Franklin Street, Toronto, OntarioM5S 2S1, Canada.
Socias ME; British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, British ColumbiaV6Z 2A9, Canada; Department of Medicine, Faculty of Medicine, University of British Columbia, 1045 Howe Street, Vancouver, British ColumbiaV6Z 2A9, Canada.
Nosyk B; Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada. Electronic address: bohdan_.
Pokaż więcej
Corporate Authors:
OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse
Źródło:
Drug and alcohol dependence [Drug Alcohol Depend] 2023 Jun 01; Vol. 247, pp. 109893. Date of Electronic Publication: 2023 Apr 23.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Opioid-Related Disorders*/drug therapy
Buprenorphine*/therapeutic use
Humans ; Methadone/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Cost-Benefit Analysis ; Opiate Substitution Treatment/methods ; Prescriptions ; Analgesics, Opioid/therapeutic use ; Narcotic Antagonists/therapeutic use
Czasopismo naukowe
Tytuł:
Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
Autorzy:
Allen E; UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Samadian S; Drug and Alcohol Services South Australia, SA Health, Adelaide, Australia.; SA Pharmacy, Statewide Clinical Support Services, SA Health, Adelaide, Australia.
Altobelli G; Drug and Alcohol Services South Australia, SA Health, Adelaide, Australia.; SA Pharmacy, Statewide Clinical Support Services, SA Health, Adelaide, Australia.
Johnson J; UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia.; SA Pharmacy, Statewide Clinical Support Services, SA Health, Adelaide, Australia.
Holmwood C; Drug and Alcohol Services South Australia, SA Health, Adelaide, Australia.
Pokaż więcej
Źródło:
Drug and alcohol review [Drug Alcohol Rev] 2023 May; Vol. 42 (4), pp. 791-802. Date of Electronic Publication: 2023 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Humans ; Opiate Substitution Treatment/methods ; Patient Satisfaction ; Australia ; Methadone ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Patient Outcome Assessment ; Analgesics, Opioid ; Narcotic Antagonists/therapeutic use
Czasopismo naukowe
Tytuł:
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Autorzy:
Baxley C; San Francisco Veterans Affairs Health Care System, 4150 Clement St, San Francisco, CA 94121, United States; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States. Electronic address: .
Borsari B; San Francisco Veterans Affairs Health Care System, 4150 Clement St, San Francisco, CA 94121, United States; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States.
Reavis JV; San Francisco Veterans Affairs Health Care System, 4150 Clement St, San Francisco, CA 94121, United States; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States; Palo Alto University, 1791 Arastradero Rd, Palo Alto, CA 94304, United States.
Manuel JK; San Francisco Veterans Affairs Health Care System, 4150 Clement St, San Francisco, CA 94121, United States; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States.
Herbst E; San Francisco Veterans Affairs Health Care System, 4150 Clement St, San Francisco, CA 94121, United States; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States.
Becker W; Yale School of Medicine, Yale University, 333 Cedar St, New Haven, CT 06510, United States; Veterans Affairs Connecticut Healthcare System, 950 Campbell Ave, West Haven, CT 06516, United States.
Pennington D; San Francisco Veterans Affairs Health Care System, 4150 Clement St, San Francisco, CA 94121, United States; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States.
Batki SL; San Francisco Veterans Affairs Health Care System, 4150 Clement St, San Francisco, CA 94121, United States; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States.
Seal K; San Francisco Veterans Affairs Health Care System, 4150 Clement St, San Francisco, CA 94121, United States; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States.
Pokaż więcej
Źródło:
Addictive behaviors [Addict Behav] 2023 Apr; Vol. 139, pp. 107589. Date of Electronic Publication: 2022 Dec 17.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Humans ; Analgesics, Opioid/therapeutic use ; Narcotic Antagonists/therapeutic use ; Craving ; Delayed-Action Preparations ; Randomized Controlled Trials as Topic ; Naltrexone/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Methadone/therapeutic use
Czasopismo naukowe
Tytuł:
Disparities in Emergency Department Naloxone and Buprenorphine Initiation.
Autorzy:
Papp J; MetroHealth Campus of Case Western Reserve University, Department of Emergency Medicine, Cleveland, Ohio.
Emerman C; MetroHealth Campus of Case Western Reserve University, Department of Emergency Medicine, Cleveland, Ohio.
Pokaż więcej
Źródło:
The western journal of emergency medicine [West J Emerg Med] 2023 Jun 30; Vol. 24 (4), pp. 710-716. Date of Electronic Publication: 2023 Jun 30.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Drug Overdose*/drug therapy
Humans ; Female ; Male ; Naloxone/therapeutic use ; Analgesics, Opioid/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Emergency Service, Hospital ; Narcotic Antagonists/therapeutic use
Czasopismo naukowe
Tytuł:
Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.
Autorzy:
Nguemeni Tiako MJ; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Center for Emergency Care and Policy Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.; Urban Health Lab, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Dolan A; Center for Emergency Care and Policy Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.; Urban Health Lab, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.; Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Abrams M; Center for Emergency Care and Policy Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.; University of Central Florida, Orlando.
Oyekanmi K; Center for Emergency Care and Policy Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.; Urban Health Lab, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.; Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Meisel Z; Center for Emergency Care and Policy Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.; Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Aronowitz SV; Center for Emergency Care and Policy Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.; Department of Family and Community Health, School of Nursing, University of Pennsylvania, Philadelphia.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2023 Jun 01; Vol. 6 (6), pp. e2318487. Date of Electronic Publication: 2023 Jun 01.
Typ publikacji:
Review; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Aged ; Humans ; United States ; Medicaid ; Prior Authorization ; Medicare ; Buprenorphine, Naloxone Drug Combination/therapeutic use
Czasopismo naukowe
Tytuł:
Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder.
Autorzy:
Kanervo MM; Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.; Doctoral Program in Clinical Research, University of Helsinki, Helsinki, Finland.
Tupola SJ; Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Nikkola EM; Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Rantakari KM; Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Kahila HK; Gynecology and Obstetrics, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Pokaż więcej
Źródło:
Acta obstetricia et gynecologica Scandinavica [Acta Obstet Gynecol Scand] 2023 Mar; Vol. 102 (3), pp. 313-322. Date of Electronic Publication: 2022 Dec 23.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Pregnancy Complications*/drug therapy
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/epidemiology
Illicit Drugs*
Female ; Infant, Newborn ; Humans ; Pregnancy ; Methadone/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Analgesics, Opioid/adverse effects ; Parturition ; Mothers
Czasopismo naukowe
Tytuł:
Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
Autorzy:
Thakrar AP; National Clinician Scholars Program at the Corporal Michael J. Crescenz Veterans Affairs Medical Center, University of Pennsylvania, Philadelphia, USA. .; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA. .
Uritsky TJ; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, USA.
Christopher C; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, USA.
Winston A; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Ronning K; School of Nursing, University of Pennsylvania, Philadelphia, USA.
Sigueza AL; School of Nursing, University of Pennsylvania, Philadelphia, USA.
Caputo A; School of Nursing, University of Pennsylvania, Philadelphia, USA.
McFadden R; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Emergency Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA.
Olenik JM; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Perrone J; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Delgado MK; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Lowenstein M; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Compton P; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Emergency Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA.
Pokaż więcej
Źródło:
Addiction science & clinical practice [Addict Sci Clin Pract] 2023 Feb 24; Vol. 18 (1), pp. 13. Date of Electronic Publication: 2023 Feb 24.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Opioid-Related Disorders*/drug therapy
Buprenorphine*/therapeutic use
Humans ; Female ; Male ; Hydromorphone ; Analgesics, Opioid/therapeutic use ; Methadone/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Naloxone/therapeutic use ; Opiate Substitution Treatment/methods ; Pain/chemically induced ; Pain/drug therapy
Czasopismo naukowe
Tytuł:
Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
Autorzy:
Azar P; Complex Pain and Addiction Services, Vancouver General Hospital, Vancouver, BC, Canada.; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Mathew N; Complex Pain and Addiction Services, Vancouver General Hospital, Vancouver, BC, Canada.; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.; Department of the Provincial Health Services Authority, BC Mental Health & Substance Use Services, Provincial Health Services Authority, BC, Canada.
Mahal D; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Wong JSH; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Westenberg JN; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Schütz CG; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.; Department of the Provincial Health Services Authority, BC Mental Health & Substance Use Services, Provincial Health Services Authority, BC, Canada.
Greenwald MK; Department of Psychiatry and Behavioral Neurosciences, School of Medicine, and Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
Pokaż więcej
Źródło:
Journal of psychoactive drugs [J Psychoactive Drugs] 2023 Jan-Mar; Vol. 55 (1), pp. 94-101. Date of Electronic Publication: 2022 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*
Opioid-Related Disorders*/drug therapy
Humans ; Analgesics, Opioid/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Opiate Substitution Treatment/methods ; Narcotic Antagonists/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies